Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Decreased activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis.
Uemura M, Matsuyama T, Ishikawa M, Fujimoto M, Kojima H, Sakurai S, Ishii S, Toyohara M, Yamazaki M, Yoshiji H, Yamao J, Matsumoto M, Ishizashi H, Fujimura Y, Fukui H. Uemura M, et al. Among authors: toyohara m. Alcohol Clin Exp Res. 2005 Dec;29(12 Suppl):264S-71S. doi: 10.1097/01.alc.0000192326.08931.cb. Alcohol Clin Exp Res. 2005. PMID: 16385234
Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C.
Yoshiji H, Noguchi R, Kojima H, Ikenaka Y, Kitade M, Kaji K, Uemura M, Yamao J, Fujimoto M, Yamazaki M, Toyohara M, Mitoro A, Fukui H. Yoshiji H, et al. Among authors: toyohara m. World J Gastroenterol. 2006 Nov 14;12(42):6786-91. doi: 10.3748/wjg.v12.i42.6786. World J Gastroenterol. 2006. PMID: 17106926 Free PMC article. Clinical Trial.
Combined treatment of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates hepatic dysplastic nodule in a patient with liver cirrhosis.
Yoshiji H, Noguchi R, Yamazaki M, Ikenaka Y, Sawai M, Ishikawa M, Kawaratani H, Mashitani T, Kitade M, Kaji K, Uemura M, Yamao J, Fujimoto M, Mitoro A, Toyohara M, Yoshida M, Fukui H. Yoshiji H, et al. Among authors: toyohara m. World J Gastroenterol. 2007 Jun 21;13(23):3259-61. doi: 10.3748/wjg.v13.i23.3259. World J Gastroenterol. 2007. PMID: 17589909 Free PMC article.
Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis.
Kitade M, Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Shirai Y, Yamazaki M, Uemura M, Yamao J, Fujimoto M, Mitoro A, Toyohara M, Sawai M, Yoshida M, Morioka C, Tsujimoto T, Kawaratani H, Fukui H. Kitade M, et al. Among authors: toyohara m. World J Gastroenterol. 2009 Nov 7;15(41):5193-9. doi: 10.3748/wjg.15.5193. World J Gastroenterol. 2009. PMID: 19891019 Free PMC article.
Combination of branched-chain amino acid and angiotensin-converting enzyme inhibitor improves liver fibrosis progression in patients with cirrhosis.
Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Aihara Y, Douhara A, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Fujimoto M, Uemura M, Fukui H. Yoshiji H, et al. Among authors: toyohara m. Mol Med Rep. 2012 Feb;5(2):539-44. doi: 10.3892/mmr.2011.676. Epub 2011 Nov 15. Mol Med Rep. 2012. PMID: 22089860 Clinical Trial.
ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the Model for End-Stage Liver Disease score.
Takaya H, Uemura M, Fujimura Y, Matsumoto M, Matsuyama T, Kato S, Morioka C, Ishizashi H, Hori Y, Fujimoto M, Tsujimoto T, Kawaratani H, Toyohara M, Kurumatani N, Fukui H. Takaya H, et al. Among authors: toyohara m. Hepatol Res. 2012 May;42(5):459-72. doi: 10.1111/j.1872-034X.2011.00950.x. Epub 2012 Jan 31. Hepatol Res. 2012. PMID: 22292786
Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report.
Mashitani T, Yoshiji H, Yamazaki M, Ikenaka Y, Noguchi R, Ishikawa M, Kawaratani H, Matsuo N, Uemura M, Yamao J, Fujimoto M, Mitoro A, Toyohara M, Yoshida M, Sawai M, Morioka C, Tsujimoto T, Kitade M, Kaji K, Aihara Y, Fukui H. Mashitani T, et al. Among authors: toyohara m. Cases J. 2009 Jan 7;2(1):18. doi: 10.1186/1757-1626-2-18. Cases J. 2009. PMID: 19128460 Free PMC article.
Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial.
Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Aihara Y, Yamazaki M, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Fujimoto M, Uemura M, Fukui H. Yoshiji H, et al. Among authors: toyohara m. Oncol Rep. 2011 Dec;26(6):1547-53. doi: 10.3892/or.2011.1433. Epub 2011 Aug 24. Oncol Rep. 2011. PMID: 21874260 Clinical Trial.
Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance.
Yoshiji H, Noguchi R, Namisaki T, Moriya K, Kitade M, Aihara Y, Douhara A, Yamao J, Fujimoto M, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Uejima M, Uemura M, Fukui H. Yoshiji H, et al. Among authors: toyohara m. Oncol Rep. 2013 Aug;30(2):545-52. doi: 10.3892/or.2013.2497. Epub 2013 May 27. Oncol Rep. 2013. PMID: 23708326 Free PMC article. Clinical Trial.
82 results